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Abstract
Introduction:	Alzheimer’s	disease	(AD)	is	the	world	leading	cause	of	dementia.	Early	
detection	of	AD	is	essential	for	faster	and	more	efficacious	usage	of	therapeutics	and	
preventive	measures.	Even	though	it	is	well	known	that	one	ε4 allele of apolipopro‐
tein	E	gene	increases	the	risk	for	sporadic	AD	five	times,	and	that	two	ε4 alleles in‐
crease	the	risk	20	times,	reliable	genetic	markers	for	AD	are	not	yet	available.	Previous	
studies	have	shown	that	microtubule‐associated	protein	tau	(MAPT) gene polymor‐
phisms	could	be	associated	with	increased	risk	for	AD.
Methods:	 The	present	 study	 included	113	AD	patients	 and	53	patients	with	mild	
cognitive	impairment	(MCI),	as	well	as	nine	healthy	controls	(HC)	and	53	patients	with	
other primary causes of dementia. The study assessed whether six MAPT	haplotype‐
tagging	polymorphisms	(rs1467967,	rs242557,	rs3785883,	rs2471738,	del–In9,	and	
rs7521) and MAPT	 haplotypes	 are	 associated	with	AD	pathology,	 as	measured	by	
cerebrospinal	fluid	(CSF)	AD	biomarkers	amyloid	β1–42	(Aβ1–42),	total	tau	(t‐tau),	tau	
phosphorylated	 at	 epitopes	 181	 (p‐tau181),	 199	 (p‐tau199),	 and	 231	 (p‐tau231), and 
visinin‐like	protein	1	(VILIP‐1).
Results:	Significant	 increases	 in	 t‐tau	and	p‐tau	CSF	 levels	were	 found	 in	patients	
with	AG	and	AA	MAPT rs1467967	genotype,	CC	MAPT rs2471738 genotype and in 
patients	with	H1H2	or	H2H2	MAPT haplotype.
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1  | INTRODUC TION
Alzheimer’s	disease	(AD),	the	most	common	primary	cause	of	de‐
mentia, is a complex disease with poorly understood etiology. The 
characteristic amyloid plaques and neurofibrillary changes seen in 
AD	brains	are	frequently	observed	in	other	neurodegenerative	dis‐
eases.	As	a	consequence,	many	AD	cases	are	misdiagnosed.	One	
such	autopsy‐confirmed	series	showed	sensitivity	of	AD	diagnosis	
to	range	from	70.9%	to	87.3%,	while	specificity	ranged	from	44.3%	
to	 70.8%	 (with	 controls	 as	 reference	 groups;	 Beach,	 Monsell,	
Phillips,	 &	 Kukull,	 2012;	 Gay,	 Taylor,	 Hohl,	 Tolnay,	 &	 Staehelin,	
2008;	 Joachim,	 Morris,	 &	 Selkoe,	 1988).	 This	 creates	 substan‐
tial difficulties in interpretations of results obtained by different 
studies	 that	 include	 patients	 with	 probable	 AD.	 One	 possibility	
to avoid this problem would be to use intermediate quantitative 
traits	 (endophenotypes)	rather	than	clinical	diagnoses	 (case–con‐
trol	studies)	as	indices	of	AD	pathology.	Endophenotypes	are	any	
biomarkers	that	signal	the	presence	of	AD	pathology.	For	example,	
for	this	study,	we	used	core	cerebrospinal	fluid	(CSF)	biomarkers	of	
AD,	such	as	amyloid	β1–42	 (Aβ1–42),	total	tau	(t‐tau),	and	tau	phos‐
phorylated	at	epitope	181	 (p‐tau181),	 and	potential	CSF	biomark‐
ers,	 such	 as	 tau	 phosphorylated	 at	 epitopes	 199	 (p‐tau199), and 
231	 (p‐tau231),	 and	visinin‐like	protein	1	 (VILIP‐1)	 as	endopheno‐
types.	Aβ1–42 indicates the presence of senile plaques in the brain 
(Grimmer	et	al.,	2009),	t‐tau	and	VILIP‐1	are	markers	of	neurode‐
generation	 (Babić	et	 al.,	 2014;	Babić	Leko,	Borovečki,	Dejanović,	
Hof,	&	Šimić,	2016),	while	p‐tau181,	 p‐tau199,	 and	p‐tau231 reflect 
the presence of neurofibrillary tangles in the brain (Bürger et 
al.,	2006).	CSF	core	biomarkers	 (Aβ1–42,	 t‐tau,	and	p‐tau181) were 
previously	 used	 in	 genome‐wide	 association	 studies	 (GWAS)	 as	
endophenotypes	 for	detection	of	AD	risk	genes	 (Cruchaga	et	al.,	
2013;	Kim	et	 al.,	 2011).	 In	 this	 study,	we	used	 these	 biomarkers	
to	assess	whether	certain	variants	of	microtubule‐associated	pro‐
tein tau (MAPT) gene were associated to their pathological levels 
in	CSF.	Although	AD	is	not	caused	by	mutations	in	the	MAPT gene, 
previous	studies	demonstrated	that	CSF	biomarkers	of	AD	differ	
among patients with different MAPT genotypes (Compta et al., 
2011;	 Kauwe	 et	 al.,	 2008).	 Besides	 comparing	 the	 levels	 of	 CSF	
biomarkers	 Aβ1–42,	 t‐tau,	 p‐tau181,	 p‐tau199,	 p‐tau231,	 and	VILIP‐1	
among patients with six different MAPT genotypes, we also an‐
alyzed	the	distribution	of	MAPT	H1	and	H2	haplotypes	and	their	
subhaplotypes in a Croatian patient cohort.
The	 majority	 of	 AD	 patients	 are	 late‐onset	 sporadic	 cases,	
whose heritability for the disease has been estimated to be as high 
as	 58%–79%	 (Gatz	 et	 al.,	 2006).	 In	 addition	 to	 apolipoprotein	 E	
gene (APOE), more than 20 common loci have been associated with 
risk	for	sporadic	AD,	age	at	onset,	and	progression	of	cognitive	de‐
cline,	but	reported	genome‐wide	significant	loci	do	not	account	for	
all the estimated heritability and provide little information about 
underlying	 biological	 mechanisms	 (Šimić	 et	 al.,	 2016a,	 2016b).	
Therefore,	genetic	studies	like	the	present	one,	using	intermediate	
quantitative	 traits	 (endophenotypes)	 such	 as	 biomarkers,	 greatly	
benefit from increased statistical power to identify variants that 
may	 not	 pass	 the	 stringent	 multiple	 test	 corrections	 in	 case– 
control studies.
2  | MATERIAL S AND METHODS
2.1 | Subjects
The	study	was	conducted	at	Clinical	Hospital	Center	Zagreb	 from	
August	2011	until	June	2016.	All	patients	signed	informed	consent	
form for lumbar puncture and for participation in this study. The con‐
sent forms were explained in details to the patients and their guard‐
ians/caregivers. The study included 116 female (F) and 112 male (M) 
subjects:	113	AD	patients	(60F/53M)	and	53	mild	cognitive	impair‐
ment	 (MCI)	patients	 (27F/26M),	nine	healthy	controls	 (HC,	6F/3M)	
and 53 patients with other causes of dementia (22 with frontotem‐
poral	 dementia	 [FTD,	 11F/11M],	 14	with	 vascular	 dementia	 [VaD,	
6F/8M], seven with dementia with Lewy bodies [DLB, 2F/5M], four 
with nonspecific dementia [ND, 3F/1M], three with mixed dementia 
[AD+VaD,	3M],	two	with	Parkinson’s	disease	[PD,	2	M],	and	one	with	
corticobasal	syndrome	[CBS]),	all	recruited	at	the	University	Hospital	
Center, Zagreb (Table 1).
This research study had a diagnostic purpose exclusively and 
was	 not	 designed	 to	 evaluate	 any	 health‐related	 interventions	
or possible effects on health outcomes. Therefore, it was not 
registered	 as	 a	 clinical	 trial.	 All	 patients	 were	 neuropsychologi‐
cally	 tested	 using	 the	 Mini‐Mental	 State	 Examination	 (MMSE),	
Montreal	 Cognitive	 Assessment	 (MoCA),	 and	 Alzheimer’s	
Disease	 Assessment	 Scale‐cognitive	 subscale	 (ADAS‐Cog),	 un‐
derwent neurological examination and complete blood tests in‐
cluding levels of vitamin B12, folic acid (B9), and thyroid function 
Conclusions: These results indicate that MAPT	haplotype‐tagging	polymorphisms	
and MAPT haplotypes	should	be	further	tested	as	potential	genetic	biomarkers	
of	AD.
K E Y W O R D S
Alzheimer's	disease,	biomarkers,	cerebrospinal	fluid,	genetic	predisposition	to	disease,	
single‐nucleotide	polymorphism,	tau	proteins
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test,	 and	had	a	negative	 serology	 for	 syphilis	or	Lyme’s	disease.	
All	 procedures	 were	 approved	 by	 the	 Ethical	 Committee	 of	
the	 Clinical	 Hospital	 Center	 Zagreb	 and	 by	 the	 Central	 Ethical	
Committee	of	the	University	of	Zagreb	Medical	School	(case	no.	
380‐59/11‐500‐77/90,	 class	 641‐01/11‐02),	 and	were	 in	 accord	
with	the	Helsinki	Declaration	(World	Medical	Association,	2013).
For	 AD,	we	 used	 diagnostic	 criteria	 of	McKhann	 et	 al.	 (2011),	
while	MCI	was	 diagnosed	 according	 to	 Petersen	 et	 al.	 (1999)	 and	
Albert	 et	 al.	 (2011).	 For	 VaD,	 we	 used	 the	 National	 Institute	 for	
Neurological	Disorders	and	Stroke—Association	Internationale	pour	
la	Recherche	et	l’Enseignement	en	Neurosciences	(NINCDS‐AIREN)	
criteria	(Román	et	al.,	1993),	as	well	as	the	Hachinski	Ischemic	Score	
(HIS)	 (Hachinski	et	al.,	1975).	The	most	 important	clinical	discrimi‐
native	factors	for	VaD	vs.	AD	are	stepwise	progression,	prominent	
impairment	 of	 the	 executive	 functions,	 higher	 probability	 of	 VaD	
when	HIS	is	>4,	and	focal	neurological	signs	implying	cortical	or	sub‐
cortical	lesions	(Desmond	et	al.,	1999).	Clinical	criteria	for	FTD	were	
based on consensus published by Neary and collaborators (Neary et 
al.,	1998).	Conditions	overlapping	AD	are	very	difficult	to	study,	but	
biomarkers	 that	we	have	chosen	are	again	superior	 in	 this	 respect	
in comparison to other approaches, such as correlation with clinical 
diagnosis.
2.2 | Lumbar puncture and ELISA analysis of CSF
Cerebrospinal	 fluid	 was	 taken	 by	 lumbar	 puncture	 between	 in‐
tervertebral	 spaces	 L3/L4	 or	 L4/L5.	 After	 centrifugation	 at	
2,000 g	 for	 10	min,	 CSF	 samples	 were	 aliquoted	 and	 stored	 in	
polypropylene	 tubes	 at	 −80°C.	 Levels	 of	 Aβ1–42,	 t‐tau,	 p‐tau231, 
p‐tau199,	p‐tau181,	and	VILIP‐1	were	determined	using	the	follow‐
ing	enzyme‐linked	immunosorbent	assays	(ELISA):	Aβ1–42 (Innotest 
β‐amyloid1–42,	 Fujirebio,	Gent,	 Belgium),	 t‐tau	 (Innotest	 hTau	Ag,	
Fujirebio),	 p‐tau231	 (Tau	 [pT231]	 Phospho‐ELISA	 Kit,	 Human,	
Thermo	 Fisher	 Scientific,	 Waltham,	 MA),	 p‐tau199	 (TAU	 [pS199]	
Phospho‐ELISA	 Kit,	 Human,	 Thermo	 Fisher	 Scientific),	 p‐tau181 
(Innotest	 Phospho‐Tau	 (181P),	 Fujirebio),	 and	 VILIP‐1	 (VILIP‐1	
Subhaplotypes htSNP alleles
Number  
of alleles
Percentage (%) 
of alleles
H1B GGGCAA 92 19.83
H1c AAGTAG 58 12.50
H1E AGGCAA 43 9.27
H1D AAGCAA 37 7.97
H1l AGACAG 30 6.47
H1u AAGCAG 17 3.66
H1h AGACAA 12 2.59
H1i GAGCAA 10 2.16
H1J AGGCAG 10 2.16
H1m GAGCAG 10 2.16
H1T AGATAG 10 2.16
H1k AAATAG 9 1.94
H1jj GGGCAG 8 1.72
H1o AAACAA 8 1.72
H1v GGATAG 7 1.51
H1q AAGTAA 6 1.29
H1g GAACAA 5 1.08
H1x GAATAG 5 1.08
H1y GAACAG 5 1.08
H1F GGACAA 4 0.86
H1p GGGTAG 3 0.65
H1aa GAGTAG 2 0.43
H1r AGGTAG 1 0.22
H2A AGGCGG 56 12.07
H2gg AGACGG 12 2.59
H2ff AAGCGG 2 0.43
H2kk AGGCGA 1 0.22
H2w GGGCGA 1 0.22
TA B L E  2  Number	of	H1	and	H2	MAPT 
subhaplotypes in the present cohort
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Human	 ELISA,	 BioVendor,	 Brno,	 Czech	 Republic),	 respectively.	
Each	 CSF	 sample	 was	 analyzed	 in	 duplicate.	 Concentrations	
ranges	of	each	biomarker	are	listed	in	Table	1.	Cutoff	values	of	CSF	
biomarkers	were	determined	by	ROC	(receiver	operating	charac‐
teristic) curve analysis.
2.3 | DNA analysis of MAPT polymorphisms
Venous	 blood	 samples	 (4	ml)	 were	 collected	 into	 plastic	 syringes	
with 1 ml of acid citrate dextrose as an anticoagulant. Genomic 
DNA	 was	 extracted	 from	 peripheral	 blood	 using	 the	 salting‐out	
method	(Miller,	Dykes,	&	Polesky,	1988).	MAPT gene polymorphisms 
(rs1467967,	rs242557,	rs3785883,	rs2471738,	del–In9,	and	rs7521)	
were	determined	using	primers	and	probes	purchased	from	Applied	
Biosystems	as	TaqMan®	SNP	Genotyping	Assay	by	ABI	Prism	7300	
Real	Time	PCR	System	apparatus	(Applied	Biosystems,	Foster	city,	
CA).	The	del‐In9	deletion	in	MAPT Intron	9	defines	the	H1/H2	MAPT 
haplotype	division	caused	by	the	inversion.	H1	and	H2	MAPT sub‐
haplotypes	were	determined	using	haplotype	 tagging	SNPs	 in	 fol‐
lowing	order:	rs1467967,	rs242557,	rs3785883,	rs2471738,	del–In9,	
and rs7521 (Table 2).
2.4 | Experimental design and statistical analysis
All	statistical	analyses	were	performed	in	SPSS	19.0.1	(SPSS,	Chicago,	
IL,	USA)	with	 the	 statistical	 significance	 level	 set	 at	α = 0.05. The 
Kolmogorov–Smirnov	test	was	used	for	assessing	data	distribution	
normality.	Regardless	of	the	results	of	the	Kolmogorov–Smirnov	test	
for normality, due to the small number of patients in certain groups, 
non	 parametric	 tests	 (Kruskal–Wallis	 test	 and	 Mann–Whitney	 U 
test)	were	used	 for	comparison	of	 the	biomarkers’	 levels	between	
groups of subjects with different MAPT genotypes and haplotypes. 
After	Kruskal–Wallis	test	for	pairwise	comparisons	of	independent	
samples, we performed the post hoc	 analysis.	 Since	 this	 post hoc 
testing	option	in	SPSS	incorporates	calculation	of	the	corrected	p‐
value, there was no need for additional corrections due to multiple 
comparisons.	Nevertheless,	due	to	the	relatively	small	sample	size,	
we performed statistical analysis with and without outliers. Only 
one statistically significant difference was lost after exclusion of 
outliers. Only results of the statistical analysis without outliers are 
presented here.
2.5 | Ethical approval
The present study was conducted according to the 6th revised 
Declaration	of	Helsinki	(Edinburgh,	2000)	and	Good	Clinical	Practice	
Guidelines and was approved by the local ethics committee of the 
Clinical	Hospital	 Centre	 Zagreb.	 All	 the	 patients	 signed	 informed	
consent form for lumbar puncture, genetic research and for par‐
ticipation in this study. The consent form was explained in details 
F I G U R E  1  Levels	of	t‐tau	in	(a)	all	patients,	(b)	AD,	MCI	patients	and	HC,	and	(c)	AD	and	MCI	patients	with	MAPT	rs1467967	genotype.	
Boxes represent the median, the 25th and 75th percentiles, and bars indicate the range of data distribution. Circles represent outliers. 
*p < 0.05
F I G U R E  2  Levels	of	p‐tau181	in	AD	and	MCI	patients	with	MAPT 
rs1467967	genotype.	Boxes	represent	the	median,	the	25th	and	
75th percentiles, and bars indicate the range of data distribution. 
Circles represent outliers. *p < 0.05
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to	the	patients	and	their	legal	guardians/caregivers.	All	procedures	
were approved by the Central Ethical Committee of the University 
of	 Zagreb	 Medical	 School	 (case	 no.	 380‐59/11‐500‐77/90,	 class	
641‐01/11‐02,	signed	on	19	May	2011).
3  | RESULTS
3.1 | Comparison of protein CSF biomarkers 
between subjects with different MAPT genotypes
The	concentrations	of	CSF	protein	biomarkers	(Aβ1–42,	t‐tau,	 	p‐
tau181,	 p‐tau199,	 p‐tau231,	 and	VILIP‐1)	 in	 the	analyzed	 subjects	
are presented in Table 1. The measured inter assay coefficient 
of	variability	(CV)	was	<10%.	The	intra	assay	CV	was	<15%	for	all	
biomarkers	used.	No	significant	differences	were	found	between	
males and females in any of the groups. There was no signifi‐
cant	difference	 in	 the	 levels	of	CSF	protein	biomarkers	 among	
subjects with different MAPT rs242557, MAPT rs3785883, and 
MAPT rs7521 genotypes.
3.2 | MAPT rs1467967 genotype
The	difference	in	t‐tau	levels	was	detected	between	patients	with	
MAPT	 rs1467967	 genotype	 (H = 11.655, df = 2, p	=	0.003).	 T‐tau	
levels	were	 significantly	higher	 in	patients	with	AG	compared	 to	
GG MAPT	 rs1467967	 genotype	 (p	=	0.002)	 and	AA	 compared	 to	
GG MAPT	rs1467967	genotype	(p = 0.022) when all patients were 
analyzed	 together	 (Figure	 1a).	 The	 observation	 of	 increased	 t‐
tau	 levels	 in	patients	with	AG	compared	to	GG	MAPT	 rs1467967	
genotype	was	 confirmed	when	 combining	AD	 and	MCI	 patients,	
and healthy controls (p	=	0.004;	 Figure	 1b)	 and	 in	 AD	 and	 MCI	
patients (p	=	0.005;	 Figure	 1c).	 The	 difference	 in	 p‐tau181 levels 
was detected between patients with MAPT	 rs1467967	genotype	
(H	=	6.955,	 df = 2, p	=	0.031).	 P‐tau181 levels were significantly 
higher	in	patients	with	AG	in	comparison	to	GG	MAPT	rs1467967	
genotype	 when	 combining	 AD	 and	 MCI	 patients	 (p = 0.025; 
Figure	2).	There	was	no	significant	difference	 in	 levels	of	Aβ1–42, 
	p‐tau199,	p‐tau231,	and	VILIP‐1	among	subjects	with	different	MAPT 
rs1467967	genotype.
3.3 | MAPT rs2471738 genotype
The	difference	 in	t‐tau	 levels	was	detected	between	patients	with	
MAPT rs2471738 genotype (H = 8.042, df = 2, p = 0.018). More 
precisely,	 t‐tau	 levels	were	significantly	higher	 in	subjects	with	CC	
in comparison to TC MAPT	 rs2471738	 genotype	 (in	 AD	 and	MCI	
patients; p	=	0.017;	 Figure	3).	 Levels	 of	 p‐tau231 were significantly 
higher	 in	subjects	with	CC	compared	to	TT	+	TC	MAPT rs2471738 
genotype (in all patients grouped together; U = 3,206, Z	=	−3.621,	
p	<	0.001;	 Figure	4a),	 in	 the	 combined	 group	of	AD,	MCI	 patients	
and healthy controls (U = 1613.5, Z	=	−3.993,	p < 0.001; Figure 4b), 
in	AD	and	MCI	patients	(U = 1,467, Z	=	−3.794,	p < 0.001; Figure 4c) 
and	in	AD	patients	(U = 671, Z	=	−3.000,	p	=	0.003;	Figure	4d).	T‐tau	
levels were significantly higher in subjects with CC in comparison to 
TT	+	TC	MAPT	rs2471738	genotype	(combining	AD,	MCI	patients	and	
healthy controls; U = 2,462.5, Z	=	−2.497,	p = 0.013; Figure 5a), and 
F I G U R E  3  Levels	of	t‐tau	in	AD	and	MCI	patients	with	MAPT 
rs2471738 genotype. Boxes represent the median, the 25th and 
75th percentiles, and bars indicate the range of data distribution. 
Circles represent outliers. *p < 0.05
F I G U R E  4  Levels	of	p‐tau231	in	(a)	all	patients,	(b)	AD,	MCI	patients	and	HC,	(c)	AD	and	MCI	patients,	and	(d)	AD	patients	with	the	MAPT 
rs2471738 genotype. Boxes represent the median, the 25th and 75th percentiles, and bars indicate the range of data distribution. Circles 
represent	outliers,	and	asterisks	represent	extreme	data	points.	*p < 0.05
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in	AD	and	MCI	patients	(U = 2,148, Z	=	−2.823,	p = 0.005; Figure 5b). 
P‐tau181 levels were significantly higher in subjects with CC in com‐
parison	to	TT	+	TC	MAPT	rs2471738	genotype	(combining	AD,	MCI	
patients and healthy controls; U = 2,485, Z	=	−2.689,	 p = 0.007; 
Figure	 5c),	 and	 in	 AD	 and	 MCI	 patients	 (U = 2,411, Z	=	−2.534,	
p = 0.011; Figure 5d). There was no significant difference in levels 
of	Aβ1–42,	p‐tau199,	and	VILIP‐1	among	subjects	with	different	MAPT 
rs2471738 genotype.
3.4 | MAPT haplotypes
In	 this	 Croatian	 cohort,	 23	 H1	 subhaplotypes	 and	 5	 H2	 subhap‐
lotypes	 were	 detected	 (Table	 2).	 T‐tau	 (U	=	3,791,	 Z	=	−2.524,	
p	=	0.012;	 Figure	 6a)	 and	 p‐tau231 (U = 3,124.5, Z	=	−2.710,	
p = 0.007; Figure 6b) levels were significantly higher in subjects with 
H1H2	+	H2H2	haplotype	compared	to	H1H1	haplotype	when	all	pa‐
tients	were	analyzed	together.
4  | DISCUSSION
This preliminary study of a Croatian cohort investigated whether 
certain variants of MAPT	gene	were	associated	with	AD	pathology	
as it was shown that polymorphisms in the MAPT gene increase the 
risk	of	tauopathies	(Di	Maria	et	al.,	2010;	Myers	et	al.,	2005;	Pittman	
et	al.,	2005).	While	a	limitation	of	this	study	is	a	low	number	of	HC	
(n	=	9),	 our	 analysis	 of	MAPT polymorphisms was conducted in all 
patients	including	the	HC	group	(228	subjects	in	total),	as	such,	the	
small	number	of	HC	 is	unlikely	 to	have	 influenced	the	outcome	of	
the	analysis.	The	levels	of	t‐tau	and	p‐tau181 were significantly higher 
in	 patients	with	 AG	 compared	 to	GG	MAPT rs1467967	 genotype.	
Levels	 of	 t‐tau	were	 significantly	 higher	 in	 patients	with	AA	 com‐
pared to GG MAPT rs1467967	genotype.	Levels	of	t‐tau	were	signifi‐
cantly higher in patients with CC compared to TC MAPT rs2471738 
genotype.	 Additionally,	 levels	 of	 t‐tau,	 p‐tau181	 and	 p‐tau231 were 
significantly higher in patients with CC compared to patients with TT 
or TC MAPT rs2471738	genotypes.	Also,	levels	of	t‐tau	and	p‐tau231 
were	significantly	higher	in	patients	with	H1H2	or	H2H2	haplotypes	
compared	to	patients	with	the	H1H1	haplotype.
Previous	 studies	 reported	 significant	differences	 in	CSF	 tau	
levels	in	carriers	of	risk	alleles	in	MAPT rs242557 (Compta et al., 
2011;	Laws	et	al.,	2007),	rs16940758,	rs3785883,	rs243511,	and	
rs2471738	 polymorphisms	 (Kauwe	 et	 al.,	 2008).	 Additionally,	
Chen	et	al.	 (2017)	 found	an	association	of	 the	A‐allele	 in	MAPT 
rs242557	polymorphism	with	increased	levels	of	t‐tau	in	plasma.	
Compta	 and	 collaborators	 found	 that	 carriers	 of	 the	A‐allele	 in	
MAPT	rs242557	polymorphism	had	increases	in	CSF	t‐tau	and	p‐
tau181 levels (Compta et al., 2011). This was observed in patients 
with	PD,	but	only	in	those	with	dementia	and	pathological	Aβ1–42 
levels	(lower	than	500	pg/ml).	Although	Compta	et	al.	compared	
F I G U R E  5  Levels	of	t‐tau	(a,	b)	and	p‐tau181	(c,	d)	in	AD,	MCI	patients	and	HC	and	in	AD	and	MCI	patients	with	the	MAPT rs2471738 
genotype. Boxes represent the median, the 25th and 75th percentiles, and bars indicate the range of data distribution. Circles represent 
outliers,	and	asterisks	represent	extreme	data	points.	*p < 0.05
F I G U R E  6  Levels	of	(a)	t‐tau	and	
(b)	p‐tau231	in	all	patients	with	H1H1	and	
H1H2	+	H2H2	MAPT haplotypes. Boxes 
represent the median, the 25th and 75th 
percentiles, and bars indicate the range of 
data distribution. Circles represent outliers, 
and	asterisks	represent	extreme	data	
points. *p < 0.05
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the	 levels	 of	 t‐tau	 and	 p‐tau181	 in	 PD	 patients	 with	 different	
MAPT rs1880753, rs1880756, rs1800547, rs1467067, rs242557, 
rs2471738, and rs7521 genotypes, they found no significant dif‐
ferences	 in	 t‐tau	 and	 p‐tau181 levels in contrast to the present 
study	that	reveals	t‐tau	and	p‐tau	levels	to	be	altered	in	patients	
with different MAPT	rs1467967	and	rs2471738	genotypes.	Elias‐
Sonnenschein	 et	 al.	 (2013)	 tested	 if	 different	MAPT	 rs1467967	
and	 rs7521	 genotypes	 affected	 the	 levels	 of	 Aβ1–42,	 t‐tau	 and	
	p‐tau181	 in	 AD	 patients.	 No	 significant	 difference	 in	 the	 levels	
of	CSF	biomarkers	between	these	patients	was	found.	However,	
MAPT	 rs2435211	 and	 rs16940758	 polymorphisms	were	 related	
to	increased	t‐tau	and	p‐tau,	respectively.	In	the	study	of	Kauwe	
et	al.	(2008)	in	which	21	SNPs	in	MAPT gene were genotyped, an 
association	of	rs16940758,	rs3785883,	rs243511,	and	rs2471738	
with	 p‐tau181	was	 observed.	 Additionally,	 these	 polymorphisms	
demonstrated	an	association	with	 t‐tau	and	p‐tau181 in patients 
with	pathological	Aβ1–42 levels. This study supports our finding 
that	t‐tau,	p‐tau181,	and	p‐tau231 levels are significantly different 
in patients with different MAPT	rs2471738	genotypes.	However,	
in contrast to our results, the association of MAPT	 rs1467967	
genotype	 with	 t‐tau	 and	 p‐tau181 that was also tested in that 
study	was	not	observed	(Kauwe	et	al.,	2008).	Although	Laws	et	
al.	 (2007)	 analyzed	 the	 association	 of	 CSF	 t‐tau	 with	 all	 poly‐
morphisms included in our study, only an association of MAPT 
rs242557	 genotype	with	 t‐tau	 levels	was	 observed.	 Laws	 et	 al.	
proposed	 that	 association	 between	 CSF	 tau	 levels	 and	 MAPT 
polymorphisms (or haplotypes) could occur through MAPT ex‐
pression.	 In	 other	words,	 individuals	 carrying	 risk	MAPT alleles 
have a higher MAPT brain expression and consequently an in‐
creased	 neurodegeneration	 and	 leakage	 of	 tau	 protein	 in	 CSF	
(Laws et al., 2007).
The study of Ning et al. (2011) showed that MAPT	 rs1467967	
polymorphism	could	serve	as	a	genetic	biomarker	for	VaD,	since	the	
rs1467967	genotypes	differed	between	VaD	patients	and	HC.	Also,	
the MAPT rs2471738 polymorphism was associated with an in‐
creased	risk	for	AD	(Vázquez‐Higuera	et	al.,	2009).	While	the	meta‐
analysis	 of	 Yuan,	Du,	Ge,	Wang,	&	Xia	 (2018)	 showed	 that	 none	
of	 the	 polymorphisms	 analyzed	 in	 the	 present	 study	 (rs1467967,	
rs3785883, rs2471738, and rs7521), except for rs242557 that 
showed	an	association	with	AD,	the	meta‐analysis	of	Zhou	and	Wang	
(2017) demonstrated an association of rs242557 and rs2471738 
polymorphisms	(but	not	rs3785883	or	rs1467967	polymorphisms)	 
with	AD.
The	association	of	the	H1U	and	H1H	haplotypes	and	H1C	hap‐
lotype	with	t‐tau	levels	was	previously	demonstrated	(Kauwe	et	al.,	
2008;	Laws	et	al.,	2007).	The	H1C	haplotype	was	shown	to	be	a	risk	
factor	 for	 progressive	 supranuclear	 palsy	 and	CBS	 (Pittman	 et	 al.,	
2005),	late‐onset	AD	(LOAD;	Myers	et	al.,	2005),	and	MCI	(Di	Maria	
et	al.,	2010),	while	the	H2	haplotype	was	associated	with	a	reduced	
risk	 for	 LOAD	 (Allen	 et	 al.,	 2014;	 Zhang	 et	 al.,	 2017).	Our	 results	
do	not	support	observations	that	individuals	with	the	H1	haplotype	
have	 increased	 CSF	 t‐tau	 levels	 (Kauwe	 et	 al.,	 2008;	 Laws	 et	 al.,	
2007)	and	 increased	risk	for	AD	or	other	tauopathies	 (Di	Maria	et	
al.,	2010;	Myers	et	al.,	2005;	Pittman	et	al.,	2005),	as	our	patients	
with	 the	H2	 haplotype	 had	 pathological	 CSF	 t‐tau	 and	 p‐tau	 lev‐
els.	However,	several	studies	failed	to	detect	the	association	of	the	
H1	haplotype	with	an	increased	risk	for	AD	(Abraham	et	al.,	2009;	
Mukherjee,	Kauwe,	Mayo,	Morris,	&	Goate,	2007;	Russ	et	al.,	2001).	
Additionally,	in	the	study	of	Min	et	al.	(2014),	patients	with	FTD	and	
MAPT	H1	 haplotype	 had	 an	 increase	 in	CSF	 p‐tau181 levels, while 
there	was	no	difference	in	the	levels	of	t‐tau.	Another	study	found	
no association between MAPT	 haplotypes	 and	CSF	 t‐tau,	 p‐tau181 
or	Aβ1–42	 levels	 (Johansson,	Zetterberg,	Håkansson,	Nissbrandt,	&	
Blennow, 2005).
In conclusion, the present study resulted in several notable 
findings. The association of MAPT	rs1467967	polymorphism	with	
AD	pathology	measured	by	levels	of	CSF	biomarkers	was	demon‐
strated,	 with	 CSF	 t‐tau	 and	 p‐tau181 levels being significantly 
higher	in	patients	with	AG	compared	to	GG	MAPT rs1467967	gen‐
otype	and	 t‐tau	 levels	being	 significantly	higher	 in	patients	with	
AA	compared	to	GG	MAPT rs1467967	genotype.	Additionally,	we	
detected an association of the MAPT rs2471738 polymorphism 
with	 AD	 pathology	 that	 was	 also	 observed	 in	 previous	 studies	
(Kauwe	et	al.,	2008;	Vázquez‐Higuera	et	al.,	2009).	However,	the	
MAPT	rs2471738	risk	allele	detected	in	our	study	(C‐allele)	differs	
from	 the	 risk	 allele	detected	 in	 the	 study	of	Myers	 et	 al.	 (2005)	
and	 Vázquez‐Higuera	 et	 al.	 (2009)	 (T‐allele),	 warranting	 further	
investigation.	We	also	observed	 an	 increase	 in	CSF	 t‐tau	 and	p‐
tau	 levels	 in	patients	with	H1H2	or	H2H2	haplotypes.	This	 find‐
ing	differs	from	studies	in	which	the	H1	haplotype	was	detected	
as	a	risk	haplotype	for	AD	and	other	tauopathies	(Di	Maria	et	al.,	
2010; Myers et al., 2005), and this issue also will require additional 
research.	 We	 used	 potentially	 novel	 CSF	 biomarkers	 of	 AD	 as	
endophenotypes	 (p‐tau199,	 p‐tau231,	 and	VILIP‐1),	while	 previous	
studies testing the association of MAPT polymorphisms	with	AD	
used	only	core	CSF	biomarkers	as	endophenotypes	(Aβ1–42,	t‐tau,	
p‐tau181).	The	p‐tau231 endophenotype showed significant differ‐
ence between groups of patients with different MAPT genotypes. 
Finally,	we	detected	23	H1	and	5	H2	MAPT subhaplotypes in this 
Croatian cohort, revealing that MAPT	haplotype‐tagging	polymor‐
phisms and MAPT haplotypes should be further tested as potential 
genetic	biomarkers	of	AD.
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